Pharmacia Invests In Spain
Swedish pharmaceutical company Pharmacia is investing 8 billion pesetas ($62.2 million) in Spain over a period of seven years. The funds will go towards the establishment of an oncology and immunology department at Spain's National Biotechnology Center (CNB), which is part of the Higher Council of Scientific Research (CSIC).
During the first year of the agreement, the Swedish company will make an initial investment of just over 1 billion pesetas. The CNB will receive 25% of the total amount that Pharmacia is investing, which is said to be to around 260 million pesetas a year.
Jose Maia Mato, president of the CSIC, said that the agreement with Pharmacia is the most important accord signed in Spain between a public research organization and a private company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze